UBS Group’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-226,458
| Closed | -$40.7M | – | 8436 |
|
|
2017
Q3 | $40.7M | Buy |
226,458
+170,614
| +306% | +$23.8M | 0.02% | 705 |
|
|
2017
Q2 | $5.79M | Buy |
55,844
+25,964
| +87% | +$2.12M | ﹤0.01% | 2014 |
|
|
2017
Q1 | $2.35M | Sell |
29,880
-76,519
| -72% | -$4.73M | ﹤0.01% | 2802 |
|
|
2016
Q4 | $4.77M | Buy |
106,399
+64,737
| +155% | +$3.18M | ﹤0.01% | 2136 |
|
|
2016
Q3 | $2.33M | Sell |
41,662
-87,509
| -68% | -$4.88M | ﹤0.01% | 2708 |
|
|
2016
Q2 | $6.46M | Buy |
129,171
+87,871
| +213% | +$4.32M | ﹤0.01% | 1731 |
|
|
2016
Q1 | $1.9M | Sell |
41,300
-147,432
| -78% | -$7.14M | ﹤0.01% | 2719 |
|
|
2015
Q4 | $11.6M | Buy |
188,732
+76,734
| +69% | +$5.4M | 0.01% | 1297 |
|
|
2015
Q3 | $6.24M | Buy |
111,998
+40,102
| +56% | +$2.52M | ﹤0.01% | 1733 |
|
|
2015
Q2 | $4.38M | Buy |
71,896
+5,942
| +9% | +$339K | ﹤0.01% | 2210 |
|
|
2015
Q1 | $3.8M | Buy |
65,954
+49,861
| +310% | +$3.34M | ﹤0.01% | 2313 |
|
|
2014
Q4 | $928K | Buy |
+16,093
| New | +$678K | ﹤0.01% | 3631 |
|
UBS Group's KITE Position: Q4 2017 in Review
UBS Group sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 226,458 shares — an estimated $40.7M sold.
UBS Group first reported a position in KITE in Q4 2014 and held it in 12 quarters. The position peaked at $40.7M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- UBS Group reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- UBS Group sold 226,458 Kite Pharma, Inc. shares in Q4 2017, an estimated $40.7M.
- UBS Group first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 12 quarters.
- UBS Group's Kite Pharma, Inc. position peaked at $40.7M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.